Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,335 result(s) found. Displaying page 2,001 of 2,217.
    «« First « Previous 1997  1998  1999  2000  2001  2002  2003  2004  2005  Next» Last»»
    EudraCT Number: 2014-002122-12 Sponsor Protocol Number: FICB2014 Start Date*: 2014-07-17
    Sponsor Name:az turnhout
    Full Title: Longitudinal Fascia Iliaca Compartment Block for Total Hip Arthroplasty
    Medical condition: Our hypothesis is that a longitudinal approach to the fascia iliaca with a larger volume of local anesthetic will decrease morphine consumption and pain scores in patients after total hip arthropla...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10044088 Total hip replacement LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005705-49 Sponsor Protocol Number: POP3study Start Date*: 2013-01-24
    Sponsor Name:zna middelheim
    Full Title: “Comparison of the onset and duration of postoperative analgesia using a popliteal block with different concentrations of local anesthetics »
    Medical condition: In our first study we were able to prove that dexamethasone prolongs total block (sensory and motor block) duration as well as time to pain when dexamaethasone is used as an additive to naropin in ...
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004865 10011123 Correction Hallux Valgus LLT
    15.1 100000004865 10019095 Hallux Valgus correction LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000416-21 Sponsor Protocol Number: CA030-001 Start Date*: 2019-01-31
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) DE (Completed) PL (Completed) FI (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000176-19 Sponsor Protocol Number: IP-IIO-622 Start Date*: 2023-01-10
    Sponsor Name:Immunophotonics Inc.
    Full Title: Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter Phase 1b/2a trial in colorectal cancer, non-small cell lung cancer, and soft tissue...
    Medical condition: Colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma patients
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029514 Non-small cell lung cancer NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010029 Colorectal cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001837-35 Sponsor Protocol Number: BPR-PIP-003 Start Date*: 2023-02-27
    Sponsor Name:Basilea Pharmaceutica International Ltd, Allschwil
    Full Title: A multicenter, open-label, single-arm, multiple-dose study to evaluate the safety, pharmacokinetics, and efficacy of ceftobiprole medocaril in term and pre-term neonates and infants up to 3 months ...
    Medical condition: Late-onset sepsis (LOS) in term and pre-term neonates and infants up to 3 months of age.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10053598 Late onset neonatal sepsis LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) LV (Prematurely Ended) SK (Completed) PL (Completed) Outside EU/EEA EE (Completed) BG (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2023-000086-14 Sponsor Protocol Number: IRST100.60 Start Date*: 2023-04-14
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospective, phase II trial
    Medical condition: Patients must have histologically or cytologically confirmation of neuroendocrine tumors or any other tumor histotype documented as sst-positive
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005046-15 Sponsor Protocol Number: KF7039-03 Start Date*: 2022-06-22
    Sponsor Name:Grünenthal GmbH
    Full Title: A single-arm, open-label, Phase III trial to evaluate the safety and tolerability of intra-articular injections of RTX-GRT7039 in subjects with moderate to severe pain associated with osteoarthrit...
    Medical condition: Moderate to severe pain associated with Osteoarthritis of the knee
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000111-69 Sponsor Protocol Number: PAC303 Start Date*: 2020-08-04
    Sponsor Name:CTI BioPharma Corp.
    Full Title: PACIFICA Phase 3: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thro...
    Medical condition: Primary Myelofibrosis, Post-essential thrombocythemia myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL), Post polycythaemia vera myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074691 Post polycythaemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074692 Post essential thrombocythaemia myelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002814-17 Sponsor Protocol Number: ID-064A301 Start Date*: 2023-04-04
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe ...
    Medical condition: Moderate to severe systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GR (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003402-40 Sponsor Protocol Number: XL184-401 Start Date*: 2015-06-16
    Sponsor Name:Exelixis, Inc.
    Full Title: A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
    Medical condition: Progressive Metastatic Medullary Thyroid Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) SE (Completed) ES (Ongoing) FR (Completed) PL (Trial now transitioned) HU (Trial now transitioned) HR (Trial now transitioned) IT (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002212-31 Sponsor Protocol Number: NEMUS Start Date*: 2021-09-27
    Sponsor Name:MIMETECH SRL
    Full Title: NEurotrophins Mimetic compound for the treatment of diabetic foot UlcerS
    Medical condition: Diabetic Foot Ulcer
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004858 10012664 Diabetic foot ulcer LLT
    24.0 100000004858 10012664 Diabetic foot ulcer LLT
    24.0 100000004858 10012664 Diabetic foot ulcer LLT
    24.0 100000004858 10012664 Diabetic foot ulcer LLT
    24.0 100000004858 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005131-74 Sponsor Protocol Number: pGBM-WBRT/DOX2020 Start Date*: 2021-02-25
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER
    Full Title: Phase II, single-arm, open-label interventional clinical trial to evaluate the role of anthracycline infusion after radiotherapy (RT) in pediatric and young adult patients with glioblastoma (pGBM)
    Medical condition: First diagnosed glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005059-35 Sponsor Protocol Number: TMP-2204-2021-47 Start Date*: 2022-01-25
    Sponsor Name:F4-Pharma GmbH i.G.
    Full Title: Potential of FX06 to improve disease severity in Acute Respiratory Distress Syndrome patients (Ixion 2.0)
    Medical condition: Acute Respiratory Distress Syndrome (ARDS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003083 ARDS LLT
    24.0 10038738 - Respiratory, thoracic and mediastinal disorders 10085269 ARDS disease progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) LT (Trial now transitioned) PT (Prematurely Ended) IT (Prematurely Ended) NL (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019102-17 Sponsor Protocol Number: Y-55-52120-147 Start Date*: Information not available in EudraCT
    Sponsor Name:Ipsen Pharma SAS
    Full Title: A PHASE III, PROSPECTIVE, MULTICENTRE, OPEN LABEL, EXTENSION STUDY ASSESSING THE LONG TERM SAFETY AND EFFICACY OF REPEATED TREATMENT WITH DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN C...
    Medical condition: Lower limb spasticity in children with dynamic equinus foot deformity due to cerebral palsy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10024132 Leg spasticity LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002876-41 Sponsor Protocol Number: 38RC18.123 Start Date*: 2019-03-27
    Sponsor Name:CHU Grenoble-Alpes
    Full Title: Assesment of Propofol sedation during intra tracheal surfactant administration by the LISA method (Less Invasive Surfactant Administration)
    Medical condition: Respiratory Distress Syndrome of preterm babies born < 32 weeks of gestational age
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003365-38 Sponsor Protocol Number: VTX958-202 Start Date*: 2023-03-31
    Sponsor Name:Ventyx Biosciences, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants with Moderately to Severely Active Crohn’s D...
    Medical condition: Moderately to severely active Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) LT (Completed) DE (Prematurely Ended) HU (Prematurely Ended) IT (Completed) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004261-26 Sponsor Protocol Number: MM-398-01-03-04 Start Date*: 2018-10-29
    Sponsor Name:Ipsen Bioscience, Inc
    Full Title: RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based...
    Medical condition: Small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Ongoing) HU (Completed) BE (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-002947-32 Sponsor Protocol Number: 02GPR2021 Start Date*: 2021-10-28
    Sponsor Name:Celon Pharma SA
    Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety and Pharmacokinetics after 2-weeks Administration of CPL207280 (GPR40 agonist) in Subjects...
    Medical condition: Type 2 Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002116-10 Sponsor Protocol Number: 40/2006/O/Sper Start Date*: 2006-05-12
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Carboplatin Gemcitabine as second line treatment in platinum sensitive advanced ovarian cancer phase II study on a new schedule.
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001727-19 Sponsor Protocol Number: 45/2006/U/Sper Start Date*: 2006-10-03
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Triamcinolone Acetonide Intravitreal Injection for the treatment for exudative maculopathy
    Medical condition: exudative maculopathy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038862 Retinal exudates LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1997  1998  1999  2000  2001  2002  2003  2004  2005  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 08:19:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA